Cost analysis of catheter ablation for paroxysmal atrial fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 1 II, 2003, Pages 292-294

  Weerasooriya, Rukshen ^a   Jaïs, Pierre ^a   Le Heuzey, Jean Yves ^b   Scaveé, Christophe ^a   Choi, Kee Joon ^a   Macle, Laurent ^a   Raybaud, Florence ^a   Hocini, Mélèze ^a   Shah, Dipen C ^a   Lavergne, Thomas ^b   Clémenty, Jacques ^a   Haïssaguerre, Michel ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Atrial fibrillation; Catheter ablation; Cost analysis

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

ADULT; AGED; CATHETER ABLATION; CONFERENCE PAPER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HOSPITAL BILLING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; RESOURCE MANAGEMENT;

EID: 0346034543     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.00035.x     Document Type: Conference Paper

References (12)

1. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France. The ALPHA study. Circulation 1999; 99:3028-3035.
2. Waldo AL, Prystowsky EN. Drug treatment of atrial fibrillation in the managed care era. Am J Cardiol 1998; 81:23C-29C.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.
4. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158:229-234.
5. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 1998; 158:1669-1677.
6. Naccarelli GV, Dell'Orfano JT, Wolbrette DL, et al. Cost-effective management of acute atrial fibrillation: Role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 2000; 1(Suppl, 1):36-45.
7. Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological end-point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101:1409-1417.
8. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins. Circulation 1999; 100:1879-1886.
9. Ching Man K, Kalbfleisch SJ, Hummel JD, et al. Safety and cost of outpatient radiofrequency ablation of the slow pathway in patients with atrioventricular nodal reentrant tachycardia. Am J Cardiol 1993; 72:1323-1324.
10. Le Heuzey JY, Plot O, Paziaud S, et al. Cost of care in atrial fibrillation. (abstract) Eur Heart J 2000; 21(Suppl.):473.
11. Kalbfleisch SJ, El-Atassi R, Calkins H. et al. Safety, feasibility and cost of outpatient radiofrequency catheter ablation of accessory atrioventricular connection. J Am Coll Cardiol 1993; 21:567-570.
12. Robbins IM, Colvin EV, Boyle TP, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Circulation 1998; 98:1769-1775.